The U.S. FDA granted accelerated approval of our BTK inhibitor for the treatment of relapsed or refractory follicular lymphoma.
Science-Based, Passion-Driven
We are advancing an innovative, high-value product portfolio for patients globally.
Passion with Purpose
We work to benefit patients wherever they live by uniting worldwide talent and resources with our vision.
Our Commitment to Patients
We offer resources to help patients and their loved ones navigate some of the complex challenges that follow the words, “You have cancer.”
BeiGene News
BeiGene Advances Leadership
09/12/2024
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
Read more
TEVIMBRA Approved
27/12/2024
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
Read more
Change Nasdaq
23/12/2024
BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
Read more